Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

White paper on microbial anti-cancer therapy and prevention.

Forbes NS, Coffin RS, Deng L, Evgin L, Fiering S, Giacalone M, Gravekamp C, Gulley JL, Gunn H, Hoffman RM, Kaur B, Liu K, Lyerly HK, Marciscano AE, Moradian E, Ruppel S, Saltzman DA, Tattersall PJ, Thorne S, Vile RG, Zhang HH, Zhou S, McFadden G.

J Immunother Cancer. 2018 Aug 6;6(1):78. doi: 10.1186/s40425-018-0381-3.

2.

Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies.

Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, Bradshaw A, Baker AT, Rizkallah PJ, Jones R, Hanna L, Hudson E, Vile RG, Chester JD, Parker AL.

Clin Cancer Res. 2018 Sep 1;24(17):4215-4224. doi: 10.1158/1078-0432.CCR-18-1089. Epub 2018 May 24.

PMID:
29798908
3.

Subversion of NK-cell and TNFα Immune Surveillance Drives Tumor Recurrence.

Kottke T, Evgin L, Shim KG, Rommelfanger D, Boisgerault N, Zaidi S, Diaz RM, Thompson J, Ilett E, Coffey M, Selby P, Pandha H, Harrington K, Melcher A, Vile R.

Cancer Immunol Res. 2017 Nov;5(11):1029-1045. doi: 10.1158/2326-6066.CIR-17-0175. Epub 2017 Oct 15.

4.

Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.

Shim KG, Zaidi S, Thompson J, Kottke T, Evgin L, Rajani KR, Schuelke M, Driscoll CB, Huff A, Pulido JS, Vile RG.

Mol Ther. 2017 Apr 5;25(4):962-975. doi: 10.1016/j.ymthe.2017.01.023. Epub 2017 Feb 22.

5.

Immunogenicity of self tumor associated proteins is enhanced through protein truncation.

Kottke T, Shim KG, Alonso-Camino V, Zaidi S, Maria Diaz R, Pulido J, Thompson J, Rajani KR, Evgin L, Ilett E, Pandha H, Harrington K, Selby P, Melcher A, Vile R.

Mol Ther Oncolytics. 2016 Dec 7;3:16030. eCollection 2016.

6.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

7.

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R.

Gene Ther. 2017 Jan;24(1):21-30. doi: 10.1038/gt.2016.70. Epub 2016 Oct 25.

8.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.

Mol Ther. 2015 Jun;23(6):1066-1076. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

9.

Aptamer-facilitated Protection of Oncolytic Virus from Neutralizing Antibodies.

Muharemagic D, Zamay A, Ghobadloo SM, Evgin L, Savitskaya A, Bell JC, Berezovski MV.

Mol Ther Nucleic Acids. 2014 Jun 3;3:e167. doi: 10.1038/mtna.2014.19.

10.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

11.

Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans.

Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH.

Nature. 2011 Aug 31;477(7362):99-102. doi: 10.1038/nature10358.

PMID:
21886163
12.

Targeting tumor vasculature with an oncolytic virus.

Breitbach CJ, De Silva NS, Falls TJ, Aladl U, Evgin L, Paterson J, Sun YY, Roy DG, Rintoul JL, Daneshmand M, Parato K, Stanford MM, Lichty BD, Fenster A, Kirn D, Atkins H, Bell JC.

Mol Ther. 2011 May;19(5):886-94. doi: 10.1038/mt.2011.26. Epub 2011 Mar 1.

13.

Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity.

Evgin L, Vähä-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM.

Mol Ther. 2010 May;18(5):896-902. doi: 10.1038/mt.2010.14. Epub 2010 Feb 16.

Supplemental Content

Support Center